Evidence map›Paper›PMID 28939487›Full record

Trial reportEBioMedicine2017

Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial.

Yan Fu, Xiao Xu, Dongsheng Huang, Dawei Cui, Lisheng Liu, Junwei Liu, Zenglei He, Jingjing Liu, Shusen Zheng, Yongzhang Luo

Registry-linked trialOpen access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02324127 (Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer), which is not on this map. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02324127 naunknown statusnot on this map

Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

TypeinterventionalSponsorBeijing Protgen Biotechnology Development Co., Ltd.Ran2012 to 2014Enrolled1,100ConditionsLiver CancerArmshsp90
3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yan FuThe National Engineering Laboratory for Anti-Tumor Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China; Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China; Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, People's Republic of China.
Xiao XuThe First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Dongsheng HuangDepartment of Surgery, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, People's Republic of China.
Dawei CuiThe National Engineering Laboratory for Anti-Tumor Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.
Lisheng LiuClinical Laboratory, Shandong Cancer Hospital, Jinan, Shandong, People's Republic of China.
Junwei LiuDepartment of Surgery, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, People's Republic of China.
Zenglei HeThe First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Jingjing LiuThe National Engineering Laboratory for Anti-Tumor Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.
Shusen ZhengThe First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China. Electronic address: shusenzheng@zju.edu.cn.
Yongzhang LuoThe National Engineering Laboratory for Anti-Tumor Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China; Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China; Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, People's Republic of China. Electronic address: yluo@tsinghua.edu.cn.
Tsinghua University · CNZhejiang University · CNShandong Tumor Hospital · CNZhejiang Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More sensitive biomarker is urgently needed to reduce the mortality caused by the worldwide prevalent liver cancer. This study aims to assess whether quantitative measurement of heat shock protein 90alpha (Hsp90α) in plasma can improve the diagnosis accuracy and monitor treatment response of liver cancer patients. We analyzed the data from an official (registered at ClinicalTrial.gov: NCT02324127), large-scale (1647 enrollments), and multicenter (three independent hospitals) clinical trial, which quantitatively measured plasma Hsp90α by ELISA for patients with liver cancer, patients with at-risk liver diseases (including hepatitis, liver cirrhosis, focal nodular hyperplasia), and healthy individuals. Diagnostic performance of plasma Hsp90α was evaluated by the calculated sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). ROC curve showed plasma Hsp90α can discriminating liver cancer with a sensitivity of 92.7% and specificity of 91.3% from non-liver cancer control. Similar results were noted in detecting early-stage liver cancer (sensitivity 91.4%, specificity 91.3%). In a parallel study compared with AFP20, plasma Hsp90α exhibited a significantly higher diagnostic performance (sensitivity 93.3% vs 61.1%) in discriminating hepatocellular carcinoma (HCC) from the control. Furthermore, plasma Hsp90α measurement maintained distinctly excellent diagnostic accuracy in distinguishing AFP-negative HCC patients (sensitivity 93.9%, specificity 91.3%) and AFP-limited liver cancer (sensitivity 96.6%, specificity 90.3%). In the efficacy monitoring study, levels of plasma Hsp90α were dramatically decreased after surgery (P=0.005), and correlated significantly with tumor size during interventional therapy (P≤0.05). These findings highlight that plasma Hsp90α as a biomarker for the diagnosis of liver cancer, and can be used to evaluate the therapeutic efficacy of liver cancer patients underwent surgery, or interventional therapy.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularFemaleHSP90 Heat-Shock ProteinsHumansLiver NeoplasmsMaleNeoplasm StagingROC CurveSensitivity and SpecificityBiomarkers, TumorHSP90AA2P protein, humanHSP90 Heat-Shock ProteinsBiomarkerLiver cancerPlasma Hsp90α

Identifiers

PMID28939487
PMCPMC5652007
OpenAlexW2756084824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.